Esmocard® 100 mg/10 ml (Solution for infusion) 

Equity Pharmaceuticals is pleased to announce the registration and availability of Esmocard®  100 mg/10 ml solution for infusion in South Africa.

Esmocard®  100 mg/10 ml (Solution for infusion) – each vial contains as active ingredient 10 mg/ml esmolol hydrochloride i.e.: 100 mg/10 ml single dose vial.

THERAPEUTIC INDICATIONS:

Supraventricular tachycardia:

  • Esmocard is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in peri-operative, post-operative, or other emergent circumstances where short-term control of ventricular rate with a short-acting agent is desirable.
  • Esmocard is also indicated in non-compensatory sinus tachycardia where, in the clinician’s judgement, the rapid heart rate requires specific intervention.

Intra-operative and post-operative tachycardia and/or hypertension:

  • Esmocard is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anaesthesia, and in the post-operative period, when in the clinician’s judgement, such specific intervention in considered indicated. Use of Esmocard to prevent such events is not recommended.
Wildcard SSL